Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials. J of Skin [Internet]. 2021 Jan. 1 [cited 2025 May 18];5(1):s11. Available from: https://skin.dermsquared.com/skin/article/view/1164